

MULTIPLE PI LEADERSHIP PLAN – PROJECT 1 – BIOMARKERS OF EPILEPTOGENESIS AFTER EXPERIMENTAL TRAUMATIC BRAIN INJURY

Project 1 of EpiBioS4Rx will have two PIs. Asla Pitkänen (University of Eastern Finland, Kuopio, Finland) will be the Project Lead (PL) and contact PI and Terence O'Brien (University of Melbourne) will be also a PI in this project. These two PIs will be responsible for coordinating the workflow across the following participating sites:

1. University of Eastern Finland, Kuopio, Finland (Project Lead, Asla Pitkänen, MD, PhD)
2. University of Melbourne, Melbourne, Australia (Subaward Site PI, Terence O'Brien, MD, PhD)

Asla Pitkänen, MD, PhD, DSc (PL, contact PI for Project 1): Dr. Pitkänen will be responsible for the communications among the Project 1 PIs and co-Is and the rest of the EpiBioS4Rx collaborators (Public Engagement and Administration Cores, IAC, and the Project 1 consultants), for matters that pertain to the goals and experiments done through Project 1, and for maintaining the procedures for blinding, randomization, and harmonizing procedures and analyses across institutions. This will include organization of teleconferences or web conferences, planning of annual meeting schedules to discuss the Project 1 progress, e-mail or phone conversations, preparation of minutes and progress reports from these events. Dr. Pitkänen with Dr. O'Brien will be planning the Project 1 investigator meetings for the harmonization of procedures and data analyses, calling and organizing the data presentation for the Public Engagement Core and EpiBios4Rx consortium meetings to discuss the progress of Project 1 and next steps. Dr. Pitkänen will be the contact PI to communicate with NINDS staff and prepare the progress reports to NINDS, if funded. The two PIs of Project 2, Drs. Pitkänen and O'Brien will organize the workflow of experiments across sites so that milestones and timelines are met, will supervise the manuscript preparation for Project 1 and decisions on authorship, and will chair the meetings of Project 1 that will decide on selection of markers for further studies in preclinical biomarker trial. Such meetings will include the Project 1 investigators, Public Engagement representative, IAC representatives, the consultants of Project 1 and the Steering committee of EpiBioS4Rx. Dr. Pitkänen will also be responsible for the maintenance and cataloguing of the biospecimens of the BioBank and their inclusion in the centralized database of the IAC and will be the contact person to investigators who are interested in collaborating by performing specific analyses on these biospecimens.

Terence O'Brien, MD (University of Melbourne) (PI for Project 1): Dr. O'Brien will be responsible for helping the coordination of procedures and analyses between the three study sites. He will alternate with Dr. Pitkänen in the communications needed among Project 1 investigators and the other EpiBioS4Rx investigators, if scheduling conflicts arise. Dr. O'Brien with Dr. Pitkänen will be planning the Project 1 investigator meetings for the harmonization of procedures and data analyses, calling and organizing the data presentation for the Public Engagement Core meetings to discuss the progress of Project 1 and next steps. The two PIs of Project 1, Drs. Pitkänen and O'Brien will keep track across sites so that milestones and timelines are met, will be supervising the manuscript preparation for Project 1 and decisions on authorship, and will be chairing the meetings of Project 1 that will decide on selection of markers for further studies in preclinical biomarker trial. Such meetings will include the Project 1 investigators, the Public Engagement representative, IAC representatives, the consultants of Project 1 and the Steering committee of EpiBioS4Rx.